



# Brain Death: Ceretec (TC-99m HMPAO Hexamethylpropylene)

## INDICATIONS:

- The assessment of brain blood flow in patients with an equivocal diagnosis of brain death.

## CONTRAINDICATIONS:

- None

## ADVERSE REACTIONS:

- Rash with generalized erythema, facial edema and fever has been reported in less than 1% of patients.
- A transient increase in blood pressure was seen in 8% of patients.

## SUPPLY AND STORAGE:

- The Ceretec vial is supplied as a sterile, non-pyrogenic, freeze-dried mixture of exametazime, stannous chloride dihydrate and sodium chloride.
- Store kit at 15° to 25° C (59° to 77°F).
- Store formulated drug for up to 30 minutes at 20° to 25° C (68° to 77°F) using appropriate radiation shielding.

## PATIENT PREPARATION:

- Patient should have a stable blood pressure.

## DOSE AND ADMINISTRATION:

- Adults: 370 MBq to 1110 MBq (10 to 30 mCi) administered intravenously.
- Children: 11.1 MBq/kg (0.3 mCi/kg) with a minimum dose of 185 MBq (5 mCi) administered intravenously.
- Inspect the radiopharmaceutical dose solution prior to administration and do not use it if it contains particulate.

## IMAGING PARAMETERS:

- Acquire flow images for 1 second per frame for at least 60 seconds. Start flow acquisition prior to injection.
- Planar images should be acquired approximately 20 minutes after injection for 500 – 1,000 kcts/image (acquire anterior, right lateral, left lateral and posterior (if possible)).
- Acquire SPECT images in addition to flow and planar if possible.

## PATIENT INSTRUCTION:

- None